ERBB2 and sarcoma: Another clinical trial phase 1/2, reported by Ahmed N. et al., which enrolled patients with human epidermal growth factor receptor 2 (HER2) positive sarcomas, explored the use of HER2-specific chimeric antigen receptor (CAR) T cells [28].